Literature DB >> 9520035

Recalcitrant pyoderma gangrenosum: treatment with thalidomide.

M S Hecker1, M G Lebwohl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9520035     DOI： 10.1016/s0190-9622(98)70513-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  7 in total

Review 1.  The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.

Authors:  S J Oliver
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 2.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

3.  Pyoderma gangrenosum: From historical perspectives to emerging investigations.

Authors:  Misty M Hobbs; Alex G Ortega-Loayza
Journal:  Int Wound J       Date:  2020-05-06       Impact factor: 3.315

4.  Disseminated pyoderma gangrenosum: role for vascular endothelial growth factor and hypoxia inducible factor-2.

Authors:  Ramon Alvin Chua; Jamie Mackelfresh; Cynthia Cohen; Vijay Varma; Levi Fried; Jack L Arbiser
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

5.  Thalidomide in dermatology: revisited.

Authors:  Iffat Hassan; Konchok Dorjay; Parvaiz Anwar
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

6.  Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case.

Authors:  Umit Yavuz Malkan; Gursel Gunes; Eylem Eliacik; Ibrahim Celalettin Haznedaroglu
Journal:  Int Med Case Rep J       Date:  2016-03-16

Review 7.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.